top of page

​

The World Health Organization (WHO) recommended the use of RTS,S/AS01 malaria vaccine for the prevention of P. falciparum malaria in children residing in regions with moderate to high transmission rates. Recently, a second vaccine, R21/Matrix-MTM, was recommended by the WHO. Implementation of both R21 and RTS,S and R21 vaccines has the potential to significantly contribute to malaria control.

RESEARCH

Strategy and approach

CAPTIVATE's innovative strategies will address significant bottlenecks in the development of malaria vaccines.

​

The main strategies involve the implementation of an advanced multistage malaria vaccine approach to increase vaccine efficacy. We will leverage innovative applications of both mRNA technology and in silico platform technologies to explore antigens crucial for the future development of combination vaccines for malaria. Additionally, CAPTIVATE is at the forefront of establishing the first European GMP sporozoite production facility.

Impact

CAPTIVATE innovative strategies not only shape project outcomes but ensure a lasting impact that will persist long after the project concludes.

​

Scientific outcomes

  1. Generating new knowledge on malaria parasite biology and host immune response

  2. Improving scientific and clinical methodology for better vaccine testing: CAPTIVATE will advance and refine existing pre-clinical (NHP) and clinical (CHMI) testing methods for malaria vaccine development.

  3. Reinforcing scientific equipment and instruments: Scientific, clinical and biomanufacturing communities use novel state-of-the-art GMP sporozoite production facility in Europe.

​

Economic/technological outcomes

  1. Enrichment of vaccine portfolio – novel malaria vaccine candidate

  2. Development of innovative mRNA vaccine manufacturing with decreased costs

  3. Development of a novel in silico platform for better immune response monitoring

  4. Establishment of new facility/reinforcing scientific equipment and instruments: Scientific, clinical and biomanufacturing communities use novel state-of-the-art GMP sporozoite production facility in Europe.

​

Societal outcomes

Decreasing avoidable morbidity and mortality: P. falciparum is an important cause of morbidity and mortality throughout large areas of sub-Saharan Africa and beyond.

Long-term wider impacts:

  1. Decreased burden of malaria

  2. Better healthcare solutions for patients: Healthcare systems benefit from strengthened research and innovation expertise, human capacities and know-how for combatting communicable and non-communicable diseases

  3. Reduced healthcare threat for citizens

  4. Deepen understanding towards better health decision-making.

  • alt.text.label.LinkedIn
  • alt.text.label.Twitter
Captivate_Logo-web_240207.png

Join European Vaccine Initiative's (CAPTIVATE's project coordinator) mailing list for updates on projects, training and funding opportunities.

Thanks for subscribing!

EN_FundedbytheEU_RGB_PORTFOLIO.png

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

​

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101081028.

Privacy Policy  |  Disclaimer  |  Contact us  |  Back to top

©2024 by European Vaccine Initiative

bottom of page